Cargando…
Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy
Immunotherapy shows a lot of promise for addressing the problems with traditional cancer treatments. Researchers and clinicians are working to create innovative immunological techniques for cancer detection and treatment that are more selective and have lower toxicity. An emerging field in cancer th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920693/ https://www.ncbi.nlm.nih.gov/pubmed/36770883 http://dx.doi.org/10.3390/molecules28031216 |
_version_ | 1784887132582576128 |
---|---|
author | Wahab, Shadma Ghazwani, Mohammed Hani, Umme Hakami, Abdulrahim R. Almehizia, Abdulrahman A. Ahmad, Wasim Ahmad, Mohammad Zaki Alam, Prawez Annadurai, Sivakumar |
author_facet | Wahab, Shadma Ghazwani, Mohammed Hani, Umme Hakami, Abdulrahim R. Almehizia, Abdulrahman A. Ahmad, Wasim Ahmad, Mohammad Zaki Alam, Prawez Annadurai, Sivakumar |
author_sort | Wahab, Shadma |
collection | PubMed |
description | Immunotherapy shows a lot of promise for addressing the problems with traditional cancer treatments. Researchers and clinicians are working to create innovative immunological techniques for cancer detection and treatment that are more selective and have lower toxicity. An emerging field in cancer therapy, immunomodulation offers patients an alternate approach to treating cancer. These therapies use the host’s natural defensive systems to identify and remove malignant cells in a targeted manner. Cancer treatment is now undergoing somewhat of a revolution due to recent developments in nanotechnology. Diverse nanomaterials (NMs) have been employed to overcome the limits of conventional anti-cancer treatments such as cytotoxic, surgery, radiation, and chemotherapy. Aside from that, NMs could interact with live cells and influence immune responses. In contrast, unexpected adverse effects such as necrosis, hypersensitivity, and inflammation might result from the immune system (IS)’s interaction with NMs. Therefore, to ensure the efficacy of immunomodulatory nanomaterials, it is essential to have a comprehensive understanding of the intricate interplay that exists between the IS and NMs. This review intends to present an overview of the current achievements, challenges, and improvements in using immunomodulatory nanomaterials (iNMs) for cancer therapy, with an emphasis on elucidating the mechanisms involved in the interaction between NMs and the immune system of the host. |
format | Online Article Text |
id | pubmed-9920693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99206932023-02-12 Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy Wahab, Shadma Ghazwani, Mohammed Hani, Umme Hakami, Abdulrahim R. Almehizia, Abdulrahman A. Ahmad, Wasim Ahmad, Mohammad Zaki Alam, Prawez Annadurai, Sivakumar Molecules Review Immunotherapy shows a lot of promise for addressing the problems with traditional cancer treatments. Researchers and clinicians are working to create innovative immunological techniques for cancer detection and treatment that are more selective and have lower toxicity. An emerging field in cancer therapy, immunomodulation offers patients an alternate approach to treating cancer. These therapies use the host’s natural defensive systems to identify and remove malignant cells in a targeted manner. Cancer treatment is now undergoing somewhat of a revolution due to recent developments in nanotechnology. Diverse nanomaterials (NMs) have been employed to overcome the limits of conventional anti-cancer treatments such as cytotoxic, surgery, radiation, and chemotherapy. Aside from that, NMs could interact with live cells and influence immune responses. In contrast, unexpected adverse effects such as necrosis, hypersensitivity, and inflammation might result from the immune system (IS)’s interaction with NMs. Therefore, to ensure the efficacy of immunomodulatory nanomaterials, it is essential to have a comprehensive understanding of the intricate interplay that exists between the IS and NMs. This review intends to present an overview of the current achievements, challenges, and improvements in using immunomodulatory nanomaterials (iNMs) for cancer therapy, with an emphasis on elucidating the mechanisms involved in the interaction between NMs and the immune system of the host. MDPI 2023-01-26 /pmc/articles/PMC9920693/ /pubmed/36770883 http://dx.doi.org/10.3390/molecules28031216 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wahab, Shadma Ghazwani, Mohammed Hani, Umme Hakami, Abdulrahim R. Almehizia, Abdulrahman A. Ahmad, Wasim Ahmad, Mohammad Zaki Alam, Prawez Annadurai, Sivakumar Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title | Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title_full | Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title_fullStr | Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title_full_unstemmed | Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title_short | Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy |
title_sort | nanomaterials-based novel immune strategies in clinical translation for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920693/ https://www.ncbi.nlm.nih.gov/pubmed/36770883 http://dx.doi.org/10.3390/molecules28031216 |
work_keys_str_mv | AT wahabshadma nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT ghazwanimohammed nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT haniumme nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT hakamiabdulrahimr nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT almehiziaabdulrahmana nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT ahmadwasim nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT ahmadmohammadzaki nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT alamprawez nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy AT annaduraisivakumar nanomaterialsbasednovelimmunestrategiesinclinicaltranslationforcancertherapy |